The world's first Blockchain BCI device – METATRON!
NeuraMATRIX's R&D focus is primarily on invasive brain-computer interfaces (BCIs), with a keen interest in the most fundamental interface hardware. Its products cover electrode materials, neural interface-specific chips, wireless multi-point interface system devices, brain signal acquisition and analysis visualization platforms, and system-level brain-computer interface platforms. Currently, NeuraMATRIX has completed a system-level chip upgrade, producing a hundred-channel chip that is only half the size of a fingernail, integrating acquisition, stimulation, and wireless interaction functionalities on a self-developed chip. Research data shows that NeuraMATRIX's system-level chip outperforms Neuralink’s product in both noise resistance and wireless capabilities.
NeuraMATRIX has developed the ‘MetaTron’ wireless frontal lobe EEG device, which integrates five acquisition channels, and began mass production at the end of 2023. Additionally, NeuraMATRIX is developing more highly integrated specialized chips, with products expected to be commercialized in the first half of 2025. By then, NeuraMATRIX's products will match Neuralink's in terms of the number of channels.
1.2 Project Background
The brain-computer interface platform targeted by this project will bring new technological tools to brain and neuroscience, offering a complete solution from hardware and supporting consumables to data services. It will assist in cutting-edge scientific exploration, disease mechanism research, innovative drug development and evaluation systems, motor assistance, prosthetic control, sensory communication, and more. In the scientific experiment instrument market, it will replace existing cable-based equipment (worth billions of dollars). In the consumer equipment market, it will replace existing imported chips, achieving higher integration, more channels, and lower power consumption with independently developed chips.
Currently, the project’s products are primarily aimed at the R&D market. The first neuro signal monitoring and analysis platform can provide a new quantitative and precise method for drug efficacy evaluation in new drug development and has already started collaborating with relevant enterprises. In scientific research system products, it has also revolutionized traditional wired brain-computer signal acquisition devices, changing the communication and acquisition methods. These products have already successfully achieved mass production, with around ten customers currently in trial use. Future cooperation will mainly target hospitals, particularly the neurology and neurosurgery departments of top-tier hospitals, to conduct clinical trials of medical devices. This will help the company develop early self-sufficiency, optimize technology iteration products, and unlock long-term significant commercial value.
https://docs.matrix.io/matrix/neurama...